

SCIENTIFIC REPORTS



OPEN

Aptamer-PEG-modified Fe₃O₄@Mn as a novel T1- and T2- dual-mode MRI contrast agent targeting hypoxia-induced cancer stem cells

Received: 06 September 2016

Accepted: 21 November 2016

Published: 15 December 2016

Haitao Zhu¹, Lirong Zhang¹, Yanfang Liu², Yuepeng Zhou¹, Kang Wang¹, Xiaodong Xie¹, Lian Song¹, Dongqing Wang¹, Chunlei Han^{1,3} & Qiuyun Chen^{1,4}

Hypoxia-induced cancer stem cells have been known to be involved in tumour metastasis, resistance to chemo/radio therapy and tumour recurrence. Magnetic Resonance Imaging is a widely used imaging tool for cancers in clinics and research. To develop T1-positive and T2-negative dual mode MRI agents for more comprehensive and accurate diagnostic information under hypoxic conditions, a hypoxia-inducible factor-1 α based aptamer and Mn(II)-modified nanoparticles D-Fe₃O₄@PMn were synthesized and characterized. *In vitro* and *in vivo* studies show that D-Fe₃O₄@PMn NPs are biocompatible and less cytotoxic and can produce significant contrast enhancement in T1- and T2-weighted MR imaging. Furthermore, the D-Fe₃O₄@PMn NPs enable targeted dual-contrast T1- and T2-weighted MR imaging of cancer cells expressing high levels of HIF-1 α and cancer stem cell-related proteins under hypoxic condition. In conclusion, NPs with HIF-1 α and Mn(II) are promising diagnostic agents for dual-mode T1 and T2 imaging by targeting cancer stem cells as they are non-toxic and biocompatible.

Hypoxia is a common feature of most solid malignancies and is associated with the activation of angiogenesis, metastasis and recurrence potential^{1,2}. Tumour hypoxia is an important negative prognostic factor. Hypoxic conditions eventually lead to the activation of hypoxia-inducible factor-1 α (HIF-1 α). HIF-1 α plays a key role in many crucial aspects of cancer biology including angiogenesis, metabolic reprogramming, the epithelial-mesenchymal transition (EMT), invasion, metastasis, and resistance to radiation therapy and chemotherapy^{3,4}. Recently, it has been confirmed that HIF-1 α also plays a critical role in the specification and/or maintenance of cancer stem cells (CSCs)^{5,6}. Cancer stem cells in tumour hypoxia regions are a response to tumour recurrence, local invasion, distant metastasis formation and treatment failure^{7,8}. Based on this knowledge, a non-invasive imaging method is urgently needed to identify hypoxic microenvironments and measure the cancer stem cells within the tumour hypoxic region, which would help facilitate personalized medicine.

For tumour hypoxia imaging, molecular imaging will likely become an important *in vivo* imaging biomarker in the future by providing a snap shot of a primary tumour and metastatic disease and in subsequent treatment response⁹. Among the molecular imaging technologies, MRI is perhaps one of the most powerful imaging methods for its superiority in soft tissue contrast¹⁰. Moreover, MRI contrast agents can increase imaging sensitivity by enhancing the contrast in regions of interest (ROI) with brighter or darker signals in T1 or T2 images. Despite many attempts to modify MRI sequences (blood oxygen level-dependent, BOLD; proton MRI, ¹H-MRI) or tailor contrast agents, there are still some challenges to overcome for more accurate measurements the hypoxic region in the tumour^{11–13}. Shimpei reported that a Gd³⁺-based T1 contrast agent can be used as a hypoxia-sensitive probe *in vitro*¹⁴. However, this study was limited to the *in vitro* environment and no further study was reported. Additionally, many Gd³⁺ complexes have relatively short residence time in the vascular system and toxicity, especially causing nephrogenic systemic fibrosis^{15,16}. Many attempts to overcome such obstacles in the use of modified

¹Department of Radiology, Affiliated Hospital of JiangSu University, Zhengjiang, Jiangsu Province, 212001, China.

²Department of Central Lab, Affiliated People's Hospital of JiangSu University, Zhengjiang, Jiangsu Province, 212002, China. ³Turku PET Centre, Turku University Hospital and University of Turku, Turku, Finland. ⁴School of Chemistry and Chemical Engineering, Jiangsu University, Zhenjiang, Jiangsu Province, 212013, China. Correspondence and requests for materials should be addressed to D.W. (email: wangdongqing71@163.com) or C.H. (email: Chunlei.Han@tyks.fi) or Q. C. (email: chenqy@ujs.edu.cn)

T2-negative particles (e.g., Fe_3O_4 , Fe_2O_3). These modifications partly address the toxicity and rapid clearance from the organism. However, because of the negative contrast effect and magnetic susceptibility artefacts, the obtained dark areas in MR images are often confused with low signal arising from surrounding tissues^{17,18}.

Because a single contrast agent has its own advantages and limitations, the combination of T1-positive and T2-negative agents into a single nanoprobe, creating T1/T2 dual-mode contrast agents (DMCAs) for MRI imaging, can give highly accurate information. The beneficial contrast effects are two-fold: the T1 imaging will give high tissue resolution while the T2 imaging gives high feasibility on the detection of diseases¹⁹. Di *et al.* reported that ultra-small super-paramagnetic iron oxide nanoparticles (USPIOs) with a core of less than 10 nm in diameter are capable of producing T1-positive and T2-negative images²⁰. Compared to the regular single T1 or T2 contrast agents, the contrast effects of USPIOs are relatively weak at the same scanning condition, especially the T2 contrast effect. Zhou and co-workers reported that GdIO nanoparticles can act as a T1 and T2 mutually enhanced dual-modal contrast agent for MR imaging²¹. Shin *et al.* presented an artefact filtering dual-modal contrast agent that can eliminate the false errors in MRI imaging²². However, these nanoparticles lack a tumour targeting capability. Yang *et al.* designed the DMCAs modified with an RGD peptide for selectively targeting $\alpha_v\beta_3$ over-expressed glioblastoma cancer cells *in vitro* and *in vivo*²³. Recently, Kim and co-workers reported IO@MO as a T1/T2 dual-mode imaging probe that can be activated and can exhibit high sensitivity and effective silencing/activation of the MR contrast effect under a tumour-reducing environment²⁴. The modified DMCAs can selectively accumulate and be activated under a tumour-specific microenvironment (the over-expressed receptors, acidic pH, hypoxia, etc.), which substantially increases the sensitivity and accuracy of tumour diagnosis. Based on this knowledge, we believe that the combined identification and mapping of tumour hypoxia with targeting the cancer stem cells subpopulation in hypoxic region would be realized using a modified dual-mode imaging probe. However, no such probe is currently available.

In this study, we developed a targeted T1/T2 dual-mode imaging probe that exhibits high sensitivity of the MR contrast effect for the special targeting of the cancer stem cell sub-population under hypoxic physiological conditions. PEG- and Mn(II)-modified magnetic nanoparticles (Fe_3O_4 @PMn) were synthesized and assembled with oligonucleotide HIF-1 α aptamers, forming D- Fe_3O_4 @PMn NPs as an MRI diagnostic agent. An aptamer is a short oligonucleotide that can fold into a unique tertiary structure that recognizes a specific target ranging from small organic molecules to proteins to cells^{25,26}. As a result of their unique advantages, such as low molecular weight, lack of immunogenicity, and higher specificity and stability, aptamers have become a notable class of targeting ligand for both diagnostics and therapeutics. Based on our previous studies, we used 5'-CTACGTGCT-3' as the aptamer sequence for the specific recognition of HIF-1 α ²⁷. An HIF-1 α -based aptamer ensures the special accumulation of D- Fe_3O_4 @PMn NPs in the hypoxic region. The physicochemical properties of these new materials are characterized using TEM, FT-IR, BET, and XRD. MTT assays were used to assess the cytocompatibility of the particles. The targeting specificity of D- Fe_3O_4 @PMn NPs were evaluated by dual mode T1- and T2-weighted MR imaging *in vitro* and *in vivo* using human pancreatic carcinoma cell lines (Panc-1 and Bxpc-3) and a xenograft of Panc-1.

Results

Preparation and characterization of multifunctional nanoparticles. The synthesis route of D- Fe_3O_4 @PMn is as shown in Fig. 1. Fe_3O_4 nanoparticles were first modified with PEGCOOH to improve biocompatibility, decrease non-specific affinity stability and allow for further coordination with Mn^{2+} to form Fe_3O_4 @PMn nanoparticles. Then, negative HIF-1 α aptamers bind on the surface of positive Fe_3O_4 @PMn, which form D- Fe_3O_4 @PMn nanoparticles. After magnetic separation, magnetic D- Fe_3O_4 @PMn nanoparticles were obtained. The whole synthesis procedure was carried out under N_2 , and the Fe_3O_4 @PMn were obtained using a magnetic precipitation method, which avoids Fe_3O_4 being oxidized to Fe_2O_3 . The D- Fe_3O_4 @PMn was characterized by FT-IR, UV-Vis and TEM. Figure 2A shows a TEM image of the as-prepared Fe_3O_4 and D- Fe_3O_4 @PMn. It is evident that the D- Fe_3O_4 @PMn NPs were well dispersed without agglomeration. Based on the TEM observation, D- Fe_3O_4 @PMn nanoparticles are round in shape with many holes on the surface, and their size is approximately 25–40 nm in diameter at room temperature. The D- Fe_3O_4 @PMn spectrum showed -CH₂- stretch signals around approximately 2897 cm^{-1} , PEG-O stretch signals around 1049 cm^{-1} , C=O stretch signals around 1638 cm^{-1} , and N-H stretch signals around 3400 cm^{-1} (Fig. 2B). The nitrogen adsorption-desorption data of D- Fe_3O_4 @PMn indicate that the pore volume and pore diameter are 0.2145 cm^3/g and 5.507 nm, respectively. The BET surface area is 14.3463 m^2/g , smaller than that of Fe_3O_4 , which was 54.3864 m^2/g (Fig. 2C and Table 1). The crystalline nature of the D- Fe_3O_4 @PMn is verified by XRD analysis (Fig. S1). The saturation magnetization of Fe_3O_4 @PMn is 65 emu/g . The pattern matches well with standard magnetite Fe_3O_4 reflection.

Cytotoxicity of the nanoparticles. In this study, we chose pancreatic cancer cell lines (Panc-1 and BxPC-3) as the model. The cytotoxicity of nanoparticles is very important in their biomedical application both *in vitro* and *in vivo*. To examine the toxicity of D- Fe_3O_4 @PMn, we incubated Panc-1 and BxPC-3 cells with different concentrations of non-target Fe_3O_4 @PMn and D- Fe_3O_4 @PMn for 24 h and 48 h. The cell viability was assessed using an MTT assay, and the results are shown in Fig. 3A–D. It is evident that the Panc-1 and BxPC-3 cells maintained greater than 80% cell viability after 24 h of incubation with 250 $\mu\text{g/mL}$ non-targeted Fe_3O_4 @PMn and D- Fe_3O_4 @PMn. Although the cytotoxicity increased with the incubation time, over 60% cell viability was still obtained. Moreover, similar results can be observed when normal human vascular endothelial cells were co-cultured with nanoparticles (Fig. 3E,F). Compared to the non-target Fe_3O_4 @PMn group, the cancer cell viabilities were lower when they were incubated with D- Fe_3O_4 @PMn, which could be attributed to the excessive uptake of nanoparticles due to the aptamer targeting effect. However, with the cancer cell viabilities there were no significant differences between the Fe_3O_4 @PMn group and the D- Fe_3O_4 @PMn group. We therefore conclude that the new multifunctional nanoparticles are biocompatible.




Figure 1. Schematic illustration of the protocol for establishment and function of D-Fe₃O₄@PMn NP.




Figure 2. Characterization of Fe₃O₄ (a) and D-Fe₃O₄@PMn NPs. (A,B) TEM images of Fe₃O₄ (A) and D-Fe₃O₄@PMn NPs (B). (C) FT-IR spectra of Fe₃O₄ (a) and D-Fe₃O₄@PMn NPs (b), indicating surface functional groups. (D) Nitrogen adsorption–desorption data of D-Fe₃O₄@PMn, indicating the pore volume and pore diameter.

In vitro cellular uptake of the nanoparticles. The intracellular uptake of the multifunctional nanoparticles was demonstrated with Panc1 and BxPC-3 cultured under hypoxic condition with and without HIF-1 α

	Pore volume (cm ³ /g)	Pore diameter (nm)	BET surface area (m ² /g)
Fe ₃ O ₄	0.2562	2.254	54.3864
D-Fe ₃ O ₄ @PMn	0.2145	5.507	14.3463

Table 1. Nitrogen adsorption–desorption data of Fe₃O₄ and DFe₃O₄@P.




Figure 3. *In vitro* toxicity of non-target Fe₃O₄@PMn and D-Fe₃O₄@PMn NPs. Viability of Panc-1 cells in the presence of the samples with varied concentrations for 24 h (A) and 48 h (B). Viability of BxPC-3 cells in the presence of the samples with varied concentrations for 24 h (C) and 48 h (D). Viability of normal HVEC cells in the presence of the samples with varied concentrations for 24 h (E) and 48 h (F).

siRNA. The targeted uptake effect of nanoparticles was evaluated both by Prussian blue staining and TEM imaging. As shown in Fig. 4A, the labelled cells showed clusters of dense blue granules in the cytoplasm after 24 h of incubation, which indicates there is iron inside the cells. Compared to the PBS and non-target Fe₃O₄@PMn nanoparticles groups, the cells have taken up a larger number of D-Fe₃O₄@PMn. With an increase in the D-Fe₃O₄@PMn concentration, a higher uptake of nanoparticles was observed. Moreover, the peak uptake concentration was 150 µg/mL. However, when the cells were cultured under normoxic conditions or under hypoxic condition with HIF-1α siRNA, the results demonstrated the less efficient cellular uptake of D-Fe₃O₄@PMn (Fig. 4B). To discover the characteristics of the cells that have a high uptake of the nanoparticles, a western blot was carried out. As shown in Fig. 4C, the higher uptake subpopulation of cells expressed a high level of HIF-1α and two cancer stem cell-related proteins, CD133 and Oct-4, indicating a better targeting ability of the D-Fe₃O₄@PMn for pancreatic




Figure 4. *In vitro* cellular uptake of the NPs. (A) Microphotographs of Prussian blue-stained Panc-1 and BxPC-3 cells in the presence of non-target Fe₃O₄@PMn and D-Fe₃O₄@PMn NPs with varied concentrations (0, 10, 50, 150, and 200 µg/mL). (B) Microphotographs of Prussian blue-stained Panc-1 and BxPC-3 cells co-cultured with D-Fe₃O₄@PMn NPs under normoxia and hypoxia with or without HIF-1α siRNA. (C) Western blot of the expression levels of HIF-1α, CD133, Oct-4 and MDR1 in the cells cultured under different conditions. (D) TEM images of the Panc-1 and BxPC-3 cells after an incubation with D-Fe₃O₄@PMn NPs (150 µg/mL).

cancer stem cells. We also test the uptake of the D-Fe₃O₄@PMn by human vascular endothelial cells under normoxia condition. The results demonstrated that D-Fe₃O₄@PMn cannot be uptake by human vascular endothelial cells (Fig. S2). Since pancreatic cancer stem cells play a key role in predicting the biological aggressiveness of cancer, the target D-Fe₃O₄@PMn will provide additional benefits for a cancer patient's therapy and diagnosis.

The intracellular distribution and uptake of D-Fe₃O₄@PMn were also characterized by TEM. As observed in Fig. 4D, majority of NPs were accumulated in vesicles and localized in the cytoplasm, which is in agreement with the Prussian blue staining. To further elucidating the mechanism of D-Fe₃O₄@PMn untargeted by pancreatic cancer stem cells, we test the expression level of MDR1. The results demonstrated that pancreatic cancer stem cells in the hypoxia condition expressed lower level MDR1 than the other two groups (Fig. 4C).

***In vitro* targeted dual mode MRI imaging.** Labelling cancer cells with nanoparticles enhances the cell-to-background contrast and makes them visible in MR images. To confirm the cancer cell special targeting ability and validate the dual mode MR imaging performance, the T1WI and T2WI MR imaging signal intensity of Panc-1 and BxPC-3 cells treated with and without D-Fe₃O₄@PMn were measured by a 3.0 T MRI system. Panc-1 cells with and without HIF-1α siRNA were incubated with different concentrations D-Fe₃O₄@PMn (10, 50, 150 µg/mL). First, we showed that the D-Fe₃O₄@PMn could be used for dual mode MR imaging. It is clear that the T1WI images got brighter with the increased concentration of D-Fe₃O₄@PMn. As a quantitative measurement of the signal intensity change displayed upon incubation with D-Fe₃O₄@PMn (150 µg/mL), the T1WI signal intensity of Panc-1/HIF-1α⁺ was 7 times higher than it was in the no-treatment control cells. Meanwhile, the T2WI images of the same cells darkened. The T2WI signal intensity of Panc-1/HIF-1α⁺ incubated with D-Fe₃O₄@PMn (150 µg/mL) was 5 times lower than the control cells without treatment (Fig. 5A and B). With increased concentrations of nanoparticles, we observed reduced signal in T2-weighted MR images and increased signal in T1-weighted MR images, indicating that these nanoparticles can act as both negative and positive contrast agents simultaneously. Second, we proved that the D-Fe₃O₄@PMn can target the HIF-1α-expressing cancer cells. HIF-1α siRNA-transfected Panc-1 cells (Panc-1/HIF-1α⁻) were treated with different concentrations of D-Fe₃O₄@PMn. As shown in Fig. 5A, the T1WI MR imaging signal intensity of Panc-1/HIF-1α⁻ cells incubated with D-Fe₃O₄@




Figure 5. *In vitro* targeted MR imaging of cancer cells. (A) T1WI MR images and signal intensity analysis for T1WI MR images of Panc-1/HIF-1 α^+ , Panc-1/HIF-1 α^- , BxPC-3/HIF-1 α^+ and BxPC-3/HIF-1 α^- incubated with varied concentrations of D-Fe $_3$ O $_4$ @PMn NPs (0, 10, 50, and 150 μ g/mL) for 24 h on 3.0 T MR system. (B) T2WI MR images and signal intensity analysis for T2WI MR images of Panc-1/HIF-1 α^+ , Panc-1/HIF-1 α^- , BxPC-3/HIF-1 α^+ and BxPC-3/HIF-1 α^- incubated with various concentrations of D-Fe $_3$ O $_4$ @PMn NPs (0, 10, 50, and 150 μ g/mL) for 24 h on 3.0 T MR system. (HIF-1 α^+ :cancer cells express high level of HIF-1 α , HIF-1 α^- : cancer cells are transfected with HIF-1 α siRNA and express a low level of HIF-1 α).

PMn (150 μ g/mL) was only approximately 1.2 times higher than that of the control cells, and the T2WI MR imaging signal intensity was just 1 times lower than the control cells. Third, we further confirmed that the Panc-1/HIF-1 α^+ subpopulation is enriched in cancer stem cells. CD133 is one of the most important markers for CSCs in a variety of solid tumours, including pancreatic carcinoma. According to the previous reports, we designated CD133 positive cells as pancreatic cancer stem cells^{28,29}. By FACS analysis, it was easily found that the proportion of CD133⁺ cells in the Panc-1/HIF-1 α^+ group (42.6 \pm 3.10%) was much larger than in the Panc-1/HIF-1 α^- group (4.39 \pm 0.36%, a 10-fold decrease in CD133 positive population; Fig. 6). This result demonstrated that the Panc-1/HIF-1 α^+ subpopulation is enriched in CD133⁺ cancer stem cells. These inspiring observations indicated the great potential of D-Fe $_3$ O $_4$ @PMn as a target-specific and efficient dual-mode contrast agent for MRI. Similar results can be observed from the BxPC-3/HIF-1 α^+ and BxPC-3/HIF-1 α^- cells (Figs 5A,B and 6).

***In vivo* targeted dual mode MR imaging.** The targeted dual mode MR imaging of cancer cells using D-Fe $_3$ O $_4$ @PMn was further performed *in vivo* using Panc-1 subcutaneous tumour-bearing nude mice. Figure 7A shows the T1WI and T2WI images of tumour modes obtained pre- and 2 h post-injection, respectively. Compared with the image without NPs injection, the T1WI images of the tumour showed a significant bright enhancement effect 2 h following the NPs injection. A quantitative measure of the signal intensity change displayed the T1WI signal intensity in the tumour was approximately 3.5 times higher than before the injection. Meanwhile, T2WI images of the tumour section darkened after the injection. The T2WI signal intensity was approximately 2 times lower than before the injection.

To study any potential changes in organ morphology in the tumour-bearing mice, histopathological examinations of the major organs (heart, lung, liver, spleen, and kidney tissue) from each treatment group were carried out to determine the possibility of nanoparticle-induced toxicity. As shown in Fig. 7B, compared to the PBS group, the oedema and vacuolization in the heart was not found, the fibrosis and the inflammatory reaction in the lung and liver samples was not detected, and the glomerular and tubular structures in the kidney samples were also clearly displayed. All these results indicated that pathological changes were not found in D-Fe $_3$ O $_4$ @PMn group.

Discussion

A solid tumour consists of highly proliferating tumour cells, which are characterized by hypoxic areas arising from an inequity between supply and consumption of oxygen. Hypoxia is a common phenomenon in malignant tumours. Many studies have demonstrated that hypoxia generally induces an aggressive tumour phenotype, such as increased invasiveness and resistance to chemotherapy. Pancreatic carcinoma is characterized by hypo-vascularization and extreme hypoxia in the early stage³⁰. Hypoxia is very common in pancreatic carcinoma.




Figure 6. HIF-1 α ⁺ cancer cells are enriched in cancer stem cells. (A) The percentage incidence of the CD133⁺ subpopulation in Panc-1 cells lines under hypoxic conditions was assessed by flow cytometry. (B) The percentage incidence of the CD133⁺ subpopulation in BxPC-3 cells lines under hypoxic condition was assessed by flow cytometry. (a) Panc-1/HIF-1 α ⁺ group. (b) Panc-1/HIF-1 α ⁻ group. (c) IgG-PE antibody for parental Panc-1 cancer cells was used as a control. (d) BxPC-3/HIF-1 α ⁺ cancer cells group. (e) BxPC-3/HIF-1 α ⁻ group. (f) IgG-PE antibody for parental BxPC-3 cancer cells was used as a control. The experiment was repeated 3 times and the data were expressed as the mean \pm standard deviation. The difference between these three groups was significant, ***P < 0.001.

Additionally, it was confirmed that several pancreatic cancer cell lines are enriched in cancer stem cells. In this study, we selected pancreatic cancer cell lines (Panc-1 and Bxpc-3) as our study model.

The tumour hypoxic environment may provide a site for the enrichment/expansion of the CSCs and successive rapid tumour progression. CSCs are undifferentiated cells with self-renewal ability that can differentiate into multiple lineages. CSCs are responsible for the genesis, growth, recurrence, and drug resistance of several tumours. This subpopulation of cells expresses distinct surface markers (CD133, CD44 and CD24) and proteins (Oct-4, Sox-2 and c-myc) and is thought to be involved in tumour origin, metastasis, recurrence and resistance to chemo-/radio-therapy^{31–33}. CD133 is considered to be a CSC marker in various solid tumours including the pancreas. In this study, we designated CD133 positive cells as pancreatic cancer stem cells, while CD133 negative cells as non cancer stem cells. CSCs have been considered to be dependent on HIF-1 α for survival and tumour growth under hypoxic condition³⁴. Recently, several lines of evidence suggest that HIF-1 α is involved in transcriptional regulation of CD133 through regulating CD133 promoter activity^{35,36}. The CSC hypothesis has attracted much attention due to its potential in the development of CSC-related diagnostics and therapies. Nanotechnology-based approaches have demonstrated significant potential in drug delivery and cancer diagnosis, and many CSC-targeting nanomedicines are being introduced, developed and evaluated in various pre-clinical studies. However, most of these agents have characteristics that limit their clinical applications, such as an off-target effect, poor water solubility, short circulation time, inconsistent stability, and unsatisfactory bio-distribution. In this study, a HIF-1 α -based multifunctional D-Fe₃O₄@PMn nanoparticle was synthesized. The cytotoxicity test revealed that the nanoparticles exhibited excellent biocompatibility *in vitro* and *in vivo*. Moreover, the new multifunctional NPs are stable under the studied pH values, temperature conditions and different aqueous media, which are essential for their further biomedical applications. As diagnostic agents, a major obstacle is their targeted delivery to specific disease sites in the body. One of the strategies to address this problem is the surface modification of the nanoparticles with target ligands. Aptamers are short oligonucleotides that can fold into unique tertiary structures that recognize a specific target ranging from small organic molecules to proteins and cells. As a result of their unique advantages, such as low molecular weight, lack of immunogenicity, and higher specificity and stability, aptamers have become a notable class of targeting ligand for both diagnostics and therapeutics. In the field of oncology, two aptamers, AS1411 and NOX-A12, inhibited tumour progression and reduced metastasis and drug resistance^{37,38}. In this study, we used the HIF-1 α -based aptamer as the guide to specially monitor the tumour hypoxia and target cancer stem cells. The tumour hypoxic condition tends to promote molecular changes and eventually lead to the activation of HIF-1 α . HIF-1 α expression is localized to the (hypoxic) pseudo-palisading cells that surround areas of necrosis. HIF-1 α also plays a key role in the maintenance of cancer stem cells. Our previous studies demonstrated that the sequence 5'-CTACGTGCT-3' was high-affinity for HIF-1 α . In this study, we selected a new special sequence that can effectively bind to the surface of positively charged Fe₃O₄@PMn and display a high affinity for HIF-1 α . Additionally, our results demonstrated that D-Fe₃O₄@PMn can be specially taken up by pancreatic cancer stem cells. To investigation mechanism for the special uptake of the NPs by the cancer stem cells, we test the expression level of MDR1 in the cancer cells. MDR1 is a member of the ABC subfamily. MDR1 is a classical pump, which binds substrates from the




Figure 7. *In vivo* targeted dual mode MR imaging. (A) T1WI MR images and signal intensity analysis for T1WI MRI of Panc-1 tumour-bearing nude mice before and after injection of D-Fe₃O₄@PMn NPs in a 3.0 T MR system. (B) T2WI MR images and signal intensity analysis for T2WI MR images of Panc-1 tumour-bearing nude mice before and after injection of D-Fe₃O₄@PMn NPs in a 3.0 T MR system. (C) H&E staining images of major organs (heart, lung, liver, spleen, and kidney) of Panc-1 tumour-bearing nude mice in groups of PBS and D-Fe₃O₄@PMn NPs (the scale bar is 50 μm).

extracellular fluid and then transports these over the membrane. MDR1 also mediates the transport of various structurally unrelated compounds endogenous compounds³⁹. We speculate that the non-target nanoparticles may be pumped out of the cell as a mechanism similar to the drug efflux mechanisms by MDR1. It is previously reported that cancer stem cells expressed higher level of MDR1. However, the cancer stem-like cells under hypoxic condition expressed lower level of MDR1. The exact mechanism needs further investigation. Previous studies have indicated that endocytosis plays a key role in nanoparticle uptake, particularly macropinocytosis and clathrin-mediated-endocytosis^{40–42}. Macropinocytosis, the main form of endocytosis, is processed by forming intracellular vesicles by closing the waving cell surface ruffles back to the plasma membrane, which provides sufficient transportation for extracellular fluid bulks and macromolecules.

Molecular imaging has demonstrated its great value to the diagnosis of cancer at an earlier stage and revealed more information about the disease at the molecular and genetic level. Among the molecular imaging technologies, MRI is perhaps one of the most powerful methods due to its superiority in soft tissue contrast and capability to provide additional details regarding tissue function, structure, and blood perfusion. Because any single contrast agent has its own advantages and limitations, the combination of T1-positive and T2-negative agents would provide more comprehensive and accurate diagnostic information and has received great attention recently. *In vitro* and *in vivo* MR imaging studies also showed that the prepared multifunctional nanoparticles are an excellent targeted T1WI-positive and T2WI-negative MR contrast agent for cancer stem cells. In the *in vivo* study, we selected a 2 h scanning time point to obtain the maximum contrast effect. According to previous publications and our previous experiments, subcutaneous tumours have a poor blood supply. The D-Fe₃O₄@PMn nanoparticles may not enter the tumour site within a short period of time. Moreover, as the solid tumour has abnormal vasculature with leakiness combined with insufficient lymphatic drainage, the nanoparticles could accumulate in the tumour tissues via the enhanced permeability and retention effect (EPR).

Conclusion

In the summary, we report a multifunctional D-Fe₃O₄@PMn nanoparticle. These high-sensitivity iron oxide nanoparticles can achieve simultaneous contrast enhancement in both T1- and T2-weighted magnetic resonance imaging and can target cancer stem cells located in hypoxic regions. This targeted new material can be potentially used as a molecular nanoprobe for tumour hypoxia diagnostic applications.

Materials and Methods

Materials and Instrumentation. Ferric chloride (FeCl₃·6H₂O), sodium acetate trihydrate (CH₃COONa·4H₂O), ethylene glycol, ethylenediamine, sodium hydroxide (NaOH), tetrahydrofuran (THF), manganese (II) acetate tetrahydrate ((CH₃COO)₂Mn·4H₂O), dicyclohexylcarbodiimide (DCC), N-Hydroxysuccinimide and PEG-NHS (MW 2000) were purchased from Sinopharm Chemical Reagent Co. Ltd. (Shanghai, China). DNA was purchased from Sangon Biotech (Shanghai, China); the sequence is listed below. Prussian blue staining assay kit and MTT cell proliferation assay kit were purchased from Life Technologies (Shanghai, China). DMEM/F12, foetal bovine serum (FBS), trypsin-EDTA and penicillin/streptomycin were purchased from Invitrogen (CA, USA). Water was purified with a Millipore Milli-Q system (25 °C, 18.2 MΩcm, 7.2 × 10⁻² Nm⁻¹). All other reagents were purchased from Sigma-Aldrich (Shanghai, China) unless specifically mentioned otherwise.

The IR spectra were recorded on a Nicolet-470 spectrophotometer (Thermo Nicolet Corporation, USA) in the range of 4000–400 cm⁻¹. The absorption spectra were recorded in the 200–800 nm regions using a Varian Cary 50-Bio UV-Vis spectrophotometer. The content of Fe and Mn in the nanoparticles was determined using an ICP-AES instrument (HORIBA Jobin Yvon, Longjumeau Cedex, France). TEM was carried out on JEOL JEM-200CX transmission electron microscope (Japan Electron Optics Laboratory Co. Ltd., Japan). X-ray diffraction (XRD) patterns of the NPs were obtained using a Philips double goniometer X'Pert system (PANalytical, St Laurent, QC) with Cu Kα radiation and recorded between 20° and 70° in the 2θ angle. Saturation magnetization was measured on an MPMS XL superconducting quantum interferometer magnetometer (Quantum Design, American) at 77 K. *In vitro* and *in vivo* MR imaging were performed using 3.0 T magnet (Magnetom Trio Tim; Siemens, Erlangen, Germany).

Synthesis of Fe₃O₄@PMn-aptamer nanoparticles (labelled as D-Fe₃O₄@PMn). Fe₃O₄@NH₂ nanoparticles were synthesized as previously reported²⁷. Fe₃O₄@NH₂ (300 mg) was mixed with PEG-NHS (2.0 g, 0.50 mmol) in DMF at 25 °C for 24 h, and then MnAc₂·4H₂O (400 mg, 1.5 mmol) was added. The mixture was stirred for 8 h. After magnetic precipitation, Fe₃O₄@PMn was obtained.

To prepare the multifunctional Fe₃O₄@PMn-aptamer conjugate, HIF-1α aptamers (5'-ACAACA AGTATGTGGAGCAACTGTGTGG-3') were used to react with Fe₃O₄@PMn obtained from the previous step. Briefly, aptamers were dissolved in Tris buffer (50 mM Tris, 100 mM NaCl). Six milligrams of Fe₃O₄@PMn NPs was dissolved in 300 μL phosphate-buffered saline (PBS, pH 7.4), to which 160 μL of the aptamer solution was added. The solution was subjected to gentle agitation for 2 h, followed by shaking for 16 h. The solution was centrifuged at 2,000 g for 10 min to separate the aptamer-NP conjugates from the unreacted aptamers. The precipitated D-Fe₃O₄@PMn NPs were resuspended in Tris buffer and finally filter-sterilized for subsequent cell culture experiments. The content of iron and manganese was 0.047 mg Fe/mg nanoparticle and 0.0725 mg Mn/mg nanoparticle, which were determined by the atomic absorption method.

Cell culture and hypoxia environmental exposure. The human vascular endothelial cells (a generous gift from Dr. Yuming, Jiangsu University, Jiangsu, China) and pancreatic cancer cell lines (Panc-1 and BxPC-3, purchased from Cell Bank of China Academy of Sciences, Shanghai, China) were cultured in DMEM-F12 supplemented with 10% FBS, 100 U/mL penicillin and 100 U/mL streptomycin in a humidified atmosphere of 95% air with 5% CO₂ at 37 °C. Cells were passaged with 0.25% trypsin/EDTA every 3 days.

For hypoxia induction, cancer cells were cultured in hypoxia chambers (Sanyo, containing 1% O₂, 5% CO₂, and 94% N₂). Nitrogen gas was supplied to the chambers to induce a controlled reduced percentage of oxygen. To assess the specificity of the NPs, siRNA technology was used. When the cell density reached 50% confluence, the cultured cells were transfected with 40 nmol/L HIF-1α-specific siRNA (Suzhou Ribo Life Science CO., Ltd). Transfections were carried out according to the manufacturer's instructions.

Cytotoxicity experiment. To evaluate the cytotoxicity of the D-Fe₃O₄@PMn, the above cultured cells were seeded onto wells of a 96-well plate at a concentration of 1 × 10⁴ cells/well and incubated for 24 h. The non-target Fe₃O₄@PMn and D-Fe₃O₄@PMn were then added to the wells to achieve the pre-determined nanoparticle concentrations ranging from 0 to 250 μg/mL for 24 h and 48 h. The cells were then gently washed with fresh medium. Finally, 100 μL of a 1 mg/ml MTT solution was added to each well, and the plate was incubated for 2 h. Then, the DMSO solution was added to each well to dissolve the formed formazan crystals, and the absorbance at 490 nm was read using an ELISA reader (ELx800, BioTek Instruments, USA). Cell viability was calculated as the mean absorbance in treated cells divided by the mean absorbance of untreated controls (back ground absorbance is subtracted). Tests were performed in triplicate.

Intracellular uptake experiments. To determine D-Fe₃O₄@PMn uptake by pancreatic cancer cells, both the Prussian blue staining technique and TEM imaging were used. For the Prussian blue staining technique, Panc-1 and BxPc-3 were cultured for 24 h in the presence of non-targeted Fe₃O₄@PMn (150 μg/mL, control) and D-Fe₃O₄@PMn (0, 10, 50, 150, 200 μg/mL) using 4-well chamber slides. Subsequently, the cells on the slide were washed twice with warm culture medium and fixed with 3.7% formaldehyde. To stain the cells on the slide, a mixture of 2.5% potassium ferrocyanide and 2.5% hydrochloric acid was used to incubate with the sample preparation for 20 min, and the slide was washed and counterstained with nuclear fast red. For TEM imaging,

pancreatic cancer cells were treated with D-Fe₃O₄@PMn (150 µg/mL), followed by fixation in 2.5% glutaraldehyde at 4 °C for 1 h. The cells were then treated with 1% osmium tetroxide, dehydrated, and embedded in AGAR100 (Nanjing Medicine University, Nanjing) before they were sliced in ultrathin sections. The resulting preparation was observed using a JEOL JEM-200CX transmission electron microscope.

Western blot analysis. Cells lysates were subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes (Merck Millipore, USA). Membranes were blocked with 5% (w/v) bovine serum albumin (BSA) in TBST for 1 h at room temperature and incubated overnight with primary antibodies at 4 °C. They were subsequently incubated with horseradish peroxidase-conjugated second antibodies. The immunoreactive bands were detected by chemiluminescence (ECL Plus, Merck Millipore) and relevant blots were quantified by densitometry using LANE-1D software. For immune detection, the primary antibody preparations were used as follows: rabbit-anti-human-Oct-4, rabbit-anti-human-CD133, rabbit-anti-human-HIF-1 α and rabbit-anti-human- β -actin. All antibodies were obtained from Cell Signaling Technology, Inc. (Boston, USA). The secondary antibody preparations, either anti-rabbit or anti-mouse, were purchased from Boster biotechnology company (Wuhan, China).

Flow cytometry analysis. Cells (5×10^6) cultured under hypoxic and normoxic conditions were harvested, disaggregated into single-cell suspensions, and stained with 1.25 µg/ml mouse anti-human phycoerythrin (PE)-labelled CD133 (clone AC133, Miltenyi Biotec. Company, CA, USA). The antibody was incubated for 30 min at 4 °C in the dark. After incubation, the samples were washed with PBS and analysed by FACS Aria II (Becton Dickinson, USA). The sorting gate was established using cells stained with isotype control PE-conjugated mouse IgG1 antibody (Miltenyi Biotec. Company).

In vitro targeted MR imaging of cancer cells. Panc-1 and BxPC-3 with and without HIF-1 α siRNA were cultured under hypoxic conditions in 6-well plates for 24 h. When the cells reached 80% confluence, the medium was replaced with 3 mL fresh medium containing different concentrations of D-Fe₃O₄@PMn (10, 50, 150 µg/mL). After another 24 h, cancer cells were washed with PBS three times, digested and collected by centrifugation (1,000 rpm for 5 min). Finally, they were dispersed in 1 mL of 1% agarose in 1.5 mL Eppendorf tubes.

For MR imaging, the cell suspension in each tube was placed in a self-designed scanning holder and then scanned using a 3.0 T clinical MR instrument with a rodent receiver coil and turbo spin-echo (TSE) sequence. The imaging parameters for the T1-weighted (T1WI) gradient-echo were set as follows: TR = 600 ms, TE = 9.2 ms, FOV = 120 mm \times 120 mm and slice thickness = 3.0 mm. The imaging parameters for the T2-weighted (T2WI) gradient-echo were set as follows: TR = 2000 ms, TE = 81.9 ms, matrix = 256 \times 256, FOV = 100 mm \times 100 mm and slice thickness = 3.0 mm. A region of interest (ROI) was selected to encompass cross sections of respective tubes. The mean T1 and T2 weighted signal intensity was measured for each cell sample.

Animal studies. Nude mice were purchased from the Animal Center of Yangzhou University and maintained in Animal Center of Jiangsu University in compliance with the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85–23, revised 1996). The experimental protocols were approved by the Committee for Ethical Affairs of Jiangsu University (Zhenjiang, China), and the methods were carried out in accordance with the approved guidelines. To demonstrate the target imaging function of pre-prepared multifunctional D-Fe₃O₄@PMn, 20 Panc-1 subcutaneous tumour-bearing nude mice were enrolled in this study and divided into two equal groups randomly. For *in vivo* MRI measurements, tumour-bearing nude mice were administered D-Fe₃O₄@PMn (5 mg/mL) diluted in PBS at a dose of 20 mg/kg by intravenous injection through the tail vein. For *in vivo* imaging, the T1WI and T2WI MR images were obtained at pre- and 2 h post-injection of the nanoparticles. The 2D fast low angle shot imaging T1-weighted imaging (2D-FLASH T1WI) sequence parameters were set as follows: TR = 280 ms, TE = 3.02 ms, FOV = 100 mm \times 100 mm, slice thickness = 2.0 mm, matrix = 192 \times 192, and flip angle = 90°. The turbo spin echo T2WI (TSE-T2WI) sequence parameters set as follows: repetition time = 3500 ms, echo time = 90 ms, flip angle = 150° and bandwidth = 260 Hz/pixel.

At day 10 after administration of the nanoparticles, the mice were sacrificed and the tissues, including the heart, liver, spleen and kidney, were removed, fixed in 10% formalin, paraffin-embedded and stained with haematoxylin and eosin (H&E) for histopathological evaluation.

Statistical analysis. Data were expressed as the mean \pm standard deviation (SD). Statistical differences were analysed by Student's t test. A value of $P < 0.05$ was considered statistically significant, and the data are marked with (*) for $P < 0.05$, (**) for $P < 0.01$, and (***) for $P < 0.001$, respectively.

References

- Wilson, W. R. & Hay, M. P. Targeting hypoxia in cancer therapy. *Nature reviews. Cancer* **11**, 393–410, doi: 10.1038/nrc3064 (2011).
- Paolicchi, E. *et al.* Targeting hypoxic response for cancer therapy. *Oncotarget* **7**, 13464–13478, doi: 10.18632/oncotarget.7229 (2016).
- Semenza, G. L. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. *Trends in pharmacological sciences* **33**, 207–214, doi: 10.1016/j.tips.2012.01.005 (2012).
- Lee, K. *et al.* Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. *Proceedings of the National Academy of Sciences of the United States of America* **106**, 17910–17915, doi: 10.1073/pnas.0909353106 (2009).
- Munoz-Pinedo, C., El Mjiyad, N. & Ricci, J. E. Cancer metabolism: current perspectives and future directions. *Cell death & disease* **3**, e248, doi: 10.1038/cddis.2011.123 (2012).
- Wang, Y., Liu, Y., Malek, S. N., Zheng, P. & Liu, Y. Targeting HIF1 α eliminates cancer stem cells in hematological malignancies. *Cell stem cell* **8**, 399–411, doi: 10.1016/j.stem.2011.02.006 (2011).
- Semenza, G. L. Dynamic regulation of stem cell specification and maintenance by hypoxia-inducible factors. *Molecular aspects of medicine* **47–48**, 15–23, doi: 10.1016/j.mam.2015.09.004 (2016).

8. Kise, K., Kinugasa-Katayama, Y. & Takakura, N. Tumor microenvironment for cancer stem cells. *Advanced drug delivery reviews* **99**, 197–205, doi: 10.1016/j.addr.2015.08.005 (2016).
9. Van Reeth, E., Tham, I. W. K., Tan, C. H. & Poh, C. L. Super-resolution in magnetic resonance imaging: A review. *Concepts In Magnetic Resonance Part A* **40A**, 306–325, doi: 10.1002/cmra.21249 (2012).
10. Yoo, D., Lee, J. H., Shin, T. H. & Cheon, J. Theranostic magnetic nanoparticles. *Accounts of chemical research* **44**, 863–874, doi: 10.1021/ar200085c (2011).
11. O'Connor, J. P. *et al.* Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer Models. *Cancer research* **76**, 787–795, doi: 10.1158/0008-5472.CAN-15-2062 (2016).
12. Hammond, E. M. *et al.* The meaning, measurement and modification of hypoxia in the laboratory and the clinic. *Clinical oncology* **26**, 277–288, doi: 10.1016/j.clon.2014.02.002 (2014).
13. Colliez, F. *et al.* Qualification of a noninvasive magnetic resonance imaging biomarker to assess tumor oxygenation. *Clinical cancer research: an official journal of the American Association for Cancer Research* **20**, 5403–5411, doi: 10.1158/1078-0432.CCR-13-3434 (2014).
14. Iwaki, S. *et al.* Development of hypoxia-sensitive Gd³⁺-based MRI contrast agents. *Bioorganic & medicinal chemistry letters* **22**, 2798–2802, doi: 10.1016/j.bmcl.2012.02.071 (2012).
15. Shokrollahi, H. Contrast agents for MRI. *Materials science & engineering. C, Materials for biological applications* **33**, 4485–4497, doi: 10.1016/j.msec.2013.07.012 (2013).
16. Szpak, A. *et al.* T1-T2 Dual-modal MRI contrast agents based on superparamagnetic iron oxide nanoparticles with surface attached gadolinium complexes. *Journal of nanoparticle research: an interdisciplinary forum for nanoscale science and technology* **16**, 2678, doi: 10.1007/s11051-014-2678-6 (2014).
17. Wei, Y. *et al.* Biocompatible Low-Retention Superparamagnetic Iron Oxide Nanoclusters as Contrast Agents for Magnetic Resonance Imaging of Liver Tumor. *Journal of biomedical nanotechnology* **11**, 854–864 (2015).
18. Estelrich, J., Sanchez-Martin, M. J. & Busquets, M. A. Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents. *International journal of nanomedicine* **10**, 1727–1741, doi: 10.2147/IJN.S76501 (2015).
19. Chen, Y. *et al.* Polydopamine-based coordination nanocomplex for T1/T2 dual mode magnetic resonance imaging-guided chemophotothermal synergistic therapy. *Biomaterials* **77**, 198–206, doi: 10.1016/j.biomaterials.2015.11.010 (2016).
20. Di Marco, M. *et al.* Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents. *International journal of nanomedicine* **2**, 609–622 (2007).
21. Zhou, Z. *et al.* A synergistically enhanced T(1)-T(2) dual-modal contrast agent. *Advanced materials* **24**, 6223–6228, doi: 10.1002/adma.201203169 (2012).
22. Shin, T. H. *et al.* T(1) and T(2) dual-mode MRI contrast agent for enhancing accuracy by engineered nanomaterials. *ACS nano* **8**, 3393–3401, doi: 10.1021/nn405977t (2014).
23. Yang, H. *et al.* Targeted dual-contrast T1- and T2-weighted magnetic resonance imaging of tumors using multifunctional gadolinium-labeled superparamagnetic iron oxide nanoparticles. *Biomaterials* **32**, 4584–4593, doi: 10.1016/j.biomaterials.2011.03.018 (2011).
24. Kim, M. H. *et al.* Redoxable heteronanocrystals functioning magnetic relaxation switch for activatable T1 and T2 dual-mode magnetic resonance imaging. *Biomaterials* **101**, 121–130, doi: 10.1016/j.biomaterials.2016.05.054 (2016).
25. Bunka, D. H. & Stockley, P. G. Aptamers come of age - at last. *Nature reviews. Microbiology* **4**, 588–596, doi: 10.1038/nrmicro1458 (2006).
26. Zhou, J., Bobbin, M. L., Burnett, J. C. & Rossi, J. J. Current progress of RNA aptamer-based therapeutics. *Frontiers in genetics* **3**, 234, doi: 10.3389/fgene.2012.00234 (2012).
27. Chen, Q. Y., Tao, G. P., Liu, Y. Q. & Yang, X. Synthesis, characterization, cell imaging and anti-tumor activity of multifunctional nanoparticles. *Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy* **96**, 284–288, doi: 10.1016/j.saa.2012.05.033 (2012).
28. Gupta, P. B., Chaffer, C. L. & Weinberg, R. A. Cancer stem cells: mirage or reality? *Nature medicine* **15**, 1010–1012, doi: 10.1038/nm0909-1010 (2009).
29. Karamitopoulou, E. Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer. *Frontiers in oncology* **2**, 209, doi: 10.3389/fonc.2012.00209 (2012).
30. Joshi, S., Kumar, S., Ponnusamy, M. P. & Batra, S. K. Hypoxia-induced oxidative stress promotes MUC4 degradation via autophagy to enhance pancreatic cancer cells survival. *Oncogene*, doi: 10.1038/onc.2016.119 (2016).
31. Heddleston, J. M. *et al.* Hypoxia inducible factors in cancer stem cells. *British Journal of Cancer* **102**, 789–795, doi: 10.1038/sj.bjc.6605551 (2010).
32. Plaks, V., Kong, N. & Werb, Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? *Cell stem cell* **16**, 225–238, doi: 10.1016/j.stem.2015.02.015 (2015).
33. Raj, D., Aicher, A. & Heeschen, C. Concise Review: Stem Cells in Pancreatic Cancer: From Concept to Translation. *Stem cells* **33**, 2893–2902, doi: 10.1002/stem.2114 (2015).
34. Vlashi, E. & Pajonk, F. Cancer stem cells, cancer cell plasticity and radiation therapy. *Seminars in cancer biology* **31**, 28–35, doi: 10.1016/j.semcancer.2014.07.001 (2015).
35. Iida, H., Suzuki, M., Goitsuka, R. & Ueno, H. Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. *International Journal of Oncology* **40**, 71–79, doi: 10.3892/ijo.2011.1207 (2012).
36. Zhu, H. *et al.* Role of the Hypoxia-inducible factor-1 alpha induced autophagy in the conversion of non-stem pancreatic cancer cells into CD133+ pancreatic cancer stem-like cells. *Cancer Cell International* **13**, 119, doi: 10.1186/1475-2867-13-119 (2013).
37. Lao, Y. H., Phua, K. K. & Leong, K. W. Aptamer nanomedicine for cancer therapeutics: barriers and potential for translation. *ACS nano* **9**, 2235–2254, doi: 10.1021/nn507494p (2015).
38. Bates, P. J., Laber, D. A., Miller, D. M., Thomas, S. D. & Trent, J. O. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. *Experimental and molecular pathology* **86**, 151–164, doi: 10.1016/j.yexmp.2009.01.004 (2009).
39. Stavrovskaya, A. A. & Stromskaya, T. P. Transport proteins of the ABC family and multidrug resistance of tumor cells. *Biochemistry (Moscow)* **73**, 592–604, doi: 10.1134/s0006297908050118 (2008).
40. Wang, X. *et al.* Epirubicin-adsorbed nanodiamonds kill chemoresistant hepatic cancer stem cells. *ACS nano* **8**, 12151–12166, doi: 10.1021/nn503491e (2014).
41. Gilleron, J. *et al.* Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. *Nature biotechnology* **31**, 638–646, doi: 10.1038/nbt.2612 (2013).
42. Kaksonen, M., Toret, C. P. & Drubin, D. G. Harnessing actin dynamics for clathrin-mediated endocytosis. *Nature reviews. Molecular cell biology* **7**, 404–414, doi: 10.1038/nrm1940 (2006).

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (Grant no. 81502663, 21571085, 21271090), the Social Development Foundation of Jiangsu Province (Grant no. BE2015668), the Key laboratory of Zhenjiang City (Grant no. SS2013017), the Social Development Foundation of Zhenjiang City (Grant no. SH2014053, SH2015053), the Six talent peals project of Jiangsu Province (2015-WSN-005), and the Clinical Medicine Foundation of Jiangsu University (JLY20140005).

Author Contributions

D.Q.W., C.L.H. and Q.Y.C. are the corresponding authors and organized the study. H.T.Z. and L.R.Z. analysed data and performed the experiments. Y.F.L., Y.P.Z. and K.W. drafted the manuscript. X.D.X. and L.S. coordinated the study and participated in its design. All authors read and approved the final manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Zhu, H. *et al.* Aptamer-PEG-modified Fe₃O₄@Mn as a novel T1- and T2- dual-model MRI contrast agent targeting hypoxia induced cancer stem cells. *Sci. Rep.* **6**, 39245; doi: 10.1038/srep39245 (2016).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016